TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01088789

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1 neo vaccine.
Description: A pancreatic vaccine secreting a granulocyte-macrophage colony-stimulating factor(GM-CSF). The vaccine consists of equal numbers of pancreatic cancer cells (Panc 6.03)and (Panc. 10.05) into a single vaccine.~The vaccine is administered every 6 months.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1 neo vaccine.
Description: A pancreatic vaccine secreting a granulocyte-macrophage colony-stimulating factor(GM-CSF). The vaccine consists of equal numbers of pancreatic cancer cells (Panc 6.03)and (Panc. 10.05) into a single vaccine.~The vaccine is administered every 6 months.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1 neo vaccine.
Description: A pancreatic vaccine secreting a granulocyte-macrophage colony-stimulating factor(GM-CSF). The vaccine consists of equal numbers of pancreatic cancer cells (Panc 6.03)and (Panc. 10.05) into a single vaccine.~The vaccine is administered every 6 months.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1 neo vaccine.
Description: A pancreatic vaccine secreting a granulocyte-macrophage colony-stimulating factor(GM-CSF). The vaccine consists of equal numbers of pancreatic cancer cells (Panc 6.03)and (Panc. 10.05) into a single vaccine.~The vaccine is administered every 6 months.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1 neo vaccine.
Description: A pancreatic vaccine secreting a granulocyte-macrophage colony-stimulating factor(GM-CSF). The vaccine consists of equal numbers of pancreatic cancer cells (Panc 6.03)and (Panc. 10.05) into a single vaccine.~The vaccine is administered every 6 months.
Study: NCT04044690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human immunoglobulin G
Description: human immunoglobulin G administered subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: contains 2% human albumin, similar excipients as IgPro20 (Hizentra), same volume, same duration, administered subcutaneously
Study: NCT00667628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAC-101
Description: Participants received TAC-101 20 mg (2 x 10-mg formulated tablets) administered orally every day with approximately 8 oz. water within 1 hour following a morning meal for 14 days followed by a 7-day recovery period, repeated every 21 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received placebo (two matching tablets) at same frequency and duration of active treatment.
Study: NCT02548546

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ECHO
Description: Imaging

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ECHO
Description: Imaging

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ECHO
Description: Imaging

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ECG-gated MRA
Description: Imaging

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ECG-gated MRA
Description: Imaging

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ECG-gated MRA
Description: Imaging
Study: NCT04601818

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental: Preserving of Donor Lungs
Description: lung transplants that have a proposed after hours start time will be delayed until 6am and the donor lungs will be preserved for no more than 12 hours at 10 degrees celsius cold static
Study: NCT04212416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Given PO
Study: NCT03486821

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation
Description: All patients on this study will receive the same type of therapy, 2 treatment hypofractionated radiation therapy.
Study: NCT01105819

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus plantarum 299 for oral care
Description: The study group will be attended in the same manor but the swabs used for cleansing are soaked with carbonated water directly from freshly opened bottles. As the final part of the procedure oral mucosal surfaces are pencilled with a suspension of the probiotic bacterium Lactobacillus plantarum 299 Cultures from the oropharynx and tracheal secretions are taken at inclusion (day 1) and then on days 2,3,5,7,10,14 and 21 or before extubation if this occurs on a non-culture day

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Chlorhexidine for standard oral care
Description: A The control group will receive the standard oral care of the department (general ICU, Lund University Hospital).~This includes suction of secretions, brushing of teeth cleansing of the oral cavity with swabs soaked with a chlorhexidine solution. This procedure is performed twice a day. In between, suction whenever needed and cleansing with swabs soaked with carbonated bottled water is performed Cultures from the oropharynx and tracheal secretions are taken at inclusion (day 1) and then on days 2,3,5,7,10,14 and 21 or before extubation if this occurs on a non-culture day
Study: NCT00271635

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 4 capsules b.i.d. during 1 year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ascorbic acid
Description: Ascorbic acid 1000 mg (4 capsules of 250 mg) b.i.d. during 1 year
Study: NCT06420804

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZIIP Acne Treatment Device
Description: Evaluation of the Safety and Efficacy of a ZIIP Acne Treatment Device
Study: NCT03388346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68 PSMA-HBED-CC PET
Description: Ga-68 PSMA-HBED-CC is an investigational PET drug (radionuclide), that binds to the prostate specific receptors. The dose will be about 5mCi (range 3-7 mCi) and administered intravenously.
Study: NCT01626326

Intervention type: BEHAVIORAL
Intervention: San Francisco Stop Smoking iPhone app
Description: iPhone app designed to help people quit smoking
Study: NCT02049775

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NBI
Study: NCT01657383

Intervention type: PROCEDURE
Intervention: HPB Surgery
Description: Hepatopancreatico Biliary Surgery
Study: NCT02931188

Intervention type: DRUG
Intervention: Anacetrapib
Description: No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)

Intervention type: DRUG
Intervention: Statin
Description: No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)

Intervention type: DRUG
Intervention: Statin
Description: No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)

Intervention type: DRUG
Intervention: Placebo
Description: No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
Study: NCT02262936

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desmopressin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fesoterodine
Study: NCT03826706

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-MAC Videolaryngoscope D blade
Description: C-MAC videolaryngoscope D blade An intubating device that is used for endotracheal intubation. Endotracheal intubation was applied by anesthesiologist with C-MAC videolaryngoscope.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-MAC Videolaryngoscope D blade
Description: C-MAC videolaryngoscope D blade An intubating device that is used for endotracheal intubation. Endotracheal intubation was applied by anesthesiologist with C-MAC videolaryngoscope.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: McGrath MAC Videolaryngoscope X3 blade
Description: McGrath MAC videolaryngoscope X blade An intubating device that is used for endotracheal intubation. Endotracheal intubation was applied by anesthesiologist with McGrath MAC videolaryngoscope.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: McGrath MAC Videolaryngoscope X3 blade
Description: McGrath MAC videolaryngoscope X blade An intubating device that is used for endotracheal intubation. Endotracheal intubation was applied by anesthesiologist with McGrath MAC videolaryngoscope.
Study: NCT01225874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC-PEG E. coli L-asparaginase
Description: Given IM
Study: NCT01493843

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paclitaxel
Description: Paclitaxel will be administered at 200 milligrams per square meter (mg/m\^2) IV on Day 1 of each 21-day cycle for a maximum of four cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel will be administered at 200 milligrams per square meter (mg/m\^2) IV on Day 1 of each 21-day cycle for a maximum of four cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paclitaxel
Description: Paclitaxel will be administered at 200 milligrams per square meter (mg/m\^2) IV on Day 1 of each 21-day cycle for a maximum of four cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel will be administered at 200 milligrams per square meter (mg/m\^2) IV on Day 1 of each 21-day cycle for a maximum of four cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paclitaxel
Description: Paclitaxel will be administered at 200 milligrams per square meter (mg/m\^2) IV on Day 1 of each 21-day cycle for a maximum of four cycles.
Study: NCT04678999

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-body exercise and education
Description: The intervention will delivered via a secure Zoom video platform.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-body exercise and education
Description: The intervention will delivered via a secure Zoom video platform.
Study: NCT01404195

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure Plus Advance
Description: Participating patients will be dispensed two small bottles daily, one at breakfast and one in the evening, seven days a week
Study: NCT01225874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study: NCT01537666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AeroVanc
Description: Vancomycin hydrochloride dry powder for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AeroVanc
Description: Vancomycin hydrochloride dry powder for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AeroVanc
Description: Vancomycin hydrochloride dry powder for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AeroVanc
Description: Vancomycin hydrochloride dry powder for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AeroVanc
Description: Vancomycin hydrochloride dry powder for inhalation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV vancomycin hydrochloride
Description: Vancomycin hydrochloride solution for intravenous administration
Study: NCT00754663

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise training
Description: walking training at least 3 times a week

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: exercise training
Description: walking training at least 3 times a week
Study: NCT03041038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Anti IL-17A antibody

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01721135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915 100mg
Description: Film coated oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915 200mg
Description: Film coated oral tablet
Study: NCT00386373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Starting dose of 100 mg daily by mouth for first 100 days following bone marrow transplant (BMT) or stem cell transplant (SCT).
Study: NCT02903264

Intervention type: OTHER
Intervention: Gestational diabetes mellitus
Study: NCT01721135

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin 400mg
Description: Film coated oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin placebo
Description: Film coated oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin placebo
Description: Film coated oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: moxifloxacin placebo
Description: Film coated oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915 placebo
Description: Film coated oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK2190915 placebo
Description: Film coated oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK2190915 placebo
Description: Film coated oral tablet
Study: NCT00005906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: Treatment with octreotide starts at a dose of 50 micrograms(ug) twice a day which is increased to 100 ug twice a day after two weeks and to 200 ug twice a day two weeks later. After two months, if there is no response the dose shall be increased to 400 ug twice a day.
Study: NCT02558894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736 monotherapy
Description: MEDI4736 via IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tremelimumab+MEDI4736
Description: tremelimumab+MEDI4736 via IV infusion.
Study: NCT01415271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet Communication
Description: bi-weekly communication of blood sugars using an internet platform between patients with type 2 diabetes and an endocrinologist
Study: NCT01258543

Intervention type: OTHER
Intervention: General Osteopathic Evaluation
Description: 2 general osteopathic evaluations of approximately 1 hour in duration done consecutively on the same day with a 15 minute break between evaluations
Study: NCT05128669

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPIP
Description: CPIP is an innovative Child-Parent Individualized Psychotherapy, consisting of 25 sessions, designed by the PI and his clinical collaborators for children with internalizing disorders in the aftermath of childhood neglect. It is informed by Short-term Psychoanalytic Child Therapy, elements of psychoanalytic parent work, videofeedback and Child-Parent Psychotherapy (CPP) and. CPIP supports the child-caregiver relationship and helps the child to resolve rigid conflictual internal representations/working models and improve interpretative and mentalizing techniques.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ECS
Description: Enhanced Caregiving Support (ECS) will serve as the control condition provided by the Allgemeine Sozialdienst (ASD - Community Social Services) of the two participating cities. According to German law (§ 27 SGB VIII), caregivers are entitled to receive caregiving support (CS; Hilfe zur Erziehung) in cases where the child's wellbeing is jeopardized. CS generally includes supportive work across all child-relevant systems (family, neighborhood, (pre-)school, peer group etc.). Appointed social workers and educators provide parenting counseling, family support, and intensive child support according to an individualized helping plan (Hilfeplan). In more severe cases, children are placed in (temporary) day-care centers, children's homes, foster families etc. Within the context of the trial, we will appoint an additional multi-systemic case manager to each case to enhance the quality of case coordination (enhanced CS; ECS). All children and families will receive ECS.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ECS
Description: Enhanced Caregiving Support (ECS) will serve as the control condition provided by the Allgemeine Sozialdienst (ASD - Community Social Services) of the two participating cities. According to German law (§ 27 SGB VIII), caregivers are entitled to receive caregiving support (CS; Hilfe zur Erziehung) in cases where the child's wellbeing is jeopardized. CS generally includes supportive work across all child-relevant systems (family, neighborhood, (pre-)school, peer group etc.). Appointed social workers and educators provide parenting counseling, family support, and intensive child support according to an individualized helping plan (Hilfeplan). In more severe cases, children are placed in (temporary) day-care centers, children's homes, foster families etc. Within the context of the trial, we will appoint an additional multi-systemic case manager to each case to enhance the quality of case coordination (enhanced CS; ECS). All children and families will receive ECS.
Study: NCT01615250

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intramyocardial implantation of stem cells
Description: Intramyocardial implantation of autologous peripheral mononuclear cells with CD34+ stem cells by NOGA.XP navigation system. Сell concentration is 200 million cells in 1 ml.
Study: NCT02928068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Performance Coaching (OPC)
Description: OPC focuses on increasing positive child-caregiver interactions and child learning opportunities in everyday routines and contexts, which positions families for improved trajectories over time. OPC capitalizes on families' strengths, while supporting caregivers in using their own resources and ideas to advance child function. Caregivers identify goals, while therapists ask reflective questions and make reflective comments, affording caregivers an opportunity to gain a deeper understanding of their own current knowledge and the impact of their strategies on their children's adaptive behavior. Thus, families generate their own solutions and are ultimately responsible for carrying out the intervention and evaluating its effectiveness.
Study: NCT04151940

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Receive standard of care chemotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Receive standard of care immunotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo standard of care radiation therapy
Study: NCT04201431

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PvDBPII/Matrix-M1
Description: 50ug PvDBPII in 50ug Matrix M1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PvDBPII/Matrix-M1
Description: 50ug PvDBPII in 50ug Matrix M1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PvDBPII/Matrix-M1
Description: 50ug PvDBPII in 50ug Matrix M1
Study: NCT04586478

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: single dose of CNCT19
Description: Dose: 2.00 x 10\^8 CNCT19 Cell Injection via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide
Study: NCT03864835

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic exercise
Description: Subjects that meet requirements for the exercise arm (12 total) will be required to exercise 30 minutes, five days per week at a moderate intensity (HR target corresponding to 45-55% of their relative VO2max). Each session will be supervised in-person at the Penn State University Fitness Center with an ACSM certified exercise physiologist. This is feasible as Zhang et al.(87) found 66 out of 70 subjects (95%) completed the twelve-month supervised in-person moderate-intensity exercise protocol five-days a week.
Study: NCT00375999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel and epirubicin
Study: NCT01754103

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tactile Training
Description: Tactile Training to induce neuroplasticity in the visual pathway, measured with functional connectivity MRI
Study: NCT02397798

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person-centered high-intense training under supervision
Description: A person-centered training program including a person-centered high-intense aerobic / strength training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personalized exercise program to perform at home
Description: Introduction to health-enhancing physical activity, personalized exercise program to perform at home three times a week
Study: NCT04251130

Intervention type: DRUG
Intervention: 2-(2-([18F]fluoro)pyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-c']dipyridine
Description: A small molecule aimed for binding and PET-imaging of aggregated tau protein in the human brain.

Intervention type: DRUG
Intervention: 2-(2-([18F]fluoro)pyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-c']dipyridine
Description: A small molecule aimed for binding and PET-imaging of aggregated tau protein in the human brain.